ArticleNPJ precision oncology2026
Landscape of circular RNAs in acute myeloid leukemia and their clinical significance.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) have emerged as important regulators in cancer biology, but their roles in acute myeloid leukemia (AML) remain poorly characterized due to limited sample sizes and technical challenges in RNA sequencing. Here, we analyze RNA-sequencing data from 315 Swedish AML patients to create the most comprehensive circRNA profile in AML to date. We identify 5,711 high-confidence circRNAs across 315 AML samples, including 402 differentially expressed between AML and healthy controls, with host genes enriched in hematopoietic pathways. We further discover two circRNAs including hsa_circ_0024048 (p = 2.16×10⁻⁶, FDR = 0.012) and hsa_circ_0084678 (p = 1.33×10⁻⁵, FDR = 0.075) whose high expression is associated with significantly improved overall survival, a relationship not observed in their respective host genes. Furthermore, these circRNAs are associated with sensitivities of several drugs, as validated in external datasets (p < 0.05). We identify 451 circRNAs with ELN2022 risk group-specific expression patterns, highlighting circRNA heterogeneity. Subtype analysis further reveals that hsa_circ_0080850 is specifically associated with worse survival (p = 2.13×10⁻
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.